Kaneko Junichi, Sugawara Yasuhiko, Maruo Yoshihiro, Sato Hiroshi, Tamura Sumihito, Imamura Hiroshi, Kokudo Norihiro, Makuuchi Masatoshi
Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Japan.
Transplantation. 2006 Jul 27;82(2):282-5. doi: 10.1097/01.tp.0000226149.31117.e4.
Serum bilirubin level is an essential factor included in the first step in evaluating living liver donor candidates. Our evaluation strategy was examined in living donors with possible Gilbert's syndrome (GS). When donor candidates had hyperbilirubinemia (>1.5 mg/dl), but otherwise normal liver function tests, their genomic DNA was isolated from leukocytes. They were diagnosed with GS when they had mutations of uridine diphosphate glucuronosyltransferase 1 typical to GS. The donors and recipients were divided into two groups: GS donors and their recipients (n = 6, each) and non-GS donors and their recipients (n = 65). All GS donors and their recipients had an unremarkable postoperative course. Total bilirubin levels of the recipients of GS donors were higher than those of recipients of non-GS donors. Living donor liver transplantation is safe for both donors with GS and their recipients.
血清胆红素水平是评估活体肝供体候选人第一步中包含的一个重要因素。我们在可能患有吉尔伯特综合征(GS)的活体供体中检验了我们的评估策略。当供体候选人出现高胆红素血症(>1.5mg/dl),但肝功能检查其他方面正常时,从白细胞中分离其基因组DNA。当他们具有GS典型的尿苷二磷酸葡萄糖醛酸基转移酶1突变时,被诊断为GS。供体和受体被分为两组:GS供体及其受体(每组n = 6)和非GS供体及其受体(n = 65)。所有GS供体及其受体术后过程均无异常。GS供体受体的总胆红素水平高于非GS供体受体。活体肝移植对患有GS的供体及其受体都是安全的。